Immunotherapeutic strategies for relapse control in acute myeloid leukemia

• Despite that the initial phases of chemotherapy induce disappearance of leukemic cells in many patients with acute myeloid leukemia (AML), the prevention of life-threatening relapses in the post-remission phase remains a significant clinical challenge. Allogeneic bone marrow transplantation, which is available for a minority of patients, efficiently prevents recurrences of leukemia by inducing immune-mediated elimination of leukemic cells, and over the past decades, numerous immunotherapeutic protocols have been developed aiming to mimic the graft-versus-leukemia reaction for the prevention of relapse. Here we review past and present strategies for relapse control with focus on overcoming leukemia-related immunosuppression in AML. We envisage future treatment protocols, in which systemic immune activators, such as vaccines, dendritic cell-based therapies, engineered variants of IL-2, or IL-15, are combined with agents that counter immunosuppression mediated by, e.g., the PD/PDL interaction, CTLA-4, CD200, reactive oxygen species, IDO expression, CXCR4, or the KIR/class I interaction, based on characteristics of the prevailing malignant clone. This combinatorial approach may pave the way for individualized immunotherapy in AML.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Acute myeloid leukemia

Maintenance therapy

Leukemia-related immunosuppression

REGULATORY T-CELLS

ACUTE MYELOGENOUS LEUKEMIA

BONE-MARROW-TRANSPLANTATION

POST-CONSOLIDATION IMMUNOTHERAPY

REMISSION

MAINTENANCE THERAPY

ACUTE PROMYELOCYTIC LEUKEMIA

KIR LIGAND

INCOMPATIBILITY

HUMORAL IMMUNE-RESPONSES

1ST COMPLETE REMISSION

LOW-DOSE INTERLEUKIN-2

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)